Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
/in Dendritic Cells, International Publications /von 2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-53[WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-2Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2010-10-28 / Blood 2011 Jan;117(2):393-402Personalized cancer vaccines
/in Dendritic Cells, International Publications /von 2010-10-28 / Expert Opin Biol Ther 2010 Dec;10(12):1637-47Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue
/in Dendritic Cells, International Publications /von 2010-10-27 / Vaccine 2010 Nov;28(51):8162-8Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2010-10-22 / BMC Cancer 2010 Oct;10:578Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-10-20 / Cancer Immunol. Immunother. 2011 Jan;60(1):123-31Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2010-10-13 / Int. J. Biol. Sci. 2010 Oct;6(7):639-48A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2010-10-05 / Br. J. Cancer 2010 Oct;103(9):1415-21IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de